> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Panel to Review AstraZeneca RSV Therapy
- URL: https://www.fdaweb.com/panel-to-review-astrazeneca-rsv-therapy/
- Published: 2023-05-03T12:00:00.000Z
- Updated: 2026-09-14T18:29:09.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5154355

*Federal Register* notice: FDA has announced a 6/8 Antimicrobial Drugs Advisory Committee meeting to discuss an AstraZeneca BLA for nirsevimab, a long-acting respiratory syncytial virus (RSV) F protein inhibitor monoclonal antibody for intramuscular use. The proposed indication is preventing RSV lower respiratory tract disease in neonates, infants and children up to 24 months of age. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2023-05-03/pdf/2023-09321.pdf?ref=fdaweb.com).